Navigation Links
Insmed to Host Second Quarter 2008 Conference Call
Date:7/25/2008

RICHMOND, Va., July 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it will host a conference call on Friday, August 8th at 8:30 AM ET, to discuss its results for the second quarter 2008. Insmed intends to issue its quarterly financial results press release before the market opens on August 8th.

To participate in the live conference call, please dial 866-202-1971 (U.S. callers) or 617-213-8842 (international), and provide passcode 85261742. A live webcast of the call will also be available at http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=1907655. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 10:30 AM ET on August 8th at 888-286-8010 (U.S. callers) or 617-801-6888 (international), using passcode 46396392.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... 2017 , ... The Catalyst Midwest premix manufacturing facility has been ... services and private label organic services. , The first organic product is Organic 18 ... officer of Dynamite Marketing, which owns the facility. , Catalyst already has received the ...
(Date:2/24/2017)... San Diego, Calif. (PRWEB) , ... February 24, 2017 , ... ... African food and wine scene. Making stops in several cities, she gained a ... Her culinary adventure began in Stellenbosch, a town in South Africa’s Western Cape province. ...
(Date:2/24/2017)... 2017 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its unaudited financial results for the third quarter and ... 31, 2016. Third Quarter of Fiscal 2017 ... of fiscal 2017 increased by 18.6% to RMB200.9 million ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... leading digital health company, and Digital Noema ... and remote patient monitoring, announce they are partnering ... DN Telehealth maximizes collaboration compatibility for ... consultations beyond a physical clinical setting to include ...
Breaking Biology Technology:
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
(Date:1/21/2017)... Research and Markets has announced the addition of the "Global ... ... recognition biometrics market to grow at a CAGR of 19.36% during ... scenario and the growth prospects of the global voice recognition biometrics ... the revenue generated from the sales of voice recognition biometrics including ...
Breaking Biology News(10 mins):